Testosterone Enanthate in Children Under 12: What Off-Label Use Actually Means

Why Testosterone Enanthate Has No Approved Label for Children Under 12

The FDA approved testosterone enanthate (Delatestryl and generics) for adult male hypogonadism and, in a secondary indication, for delayed puberty in males. The delayed-puberty indication specifies adolescent males, not prepubertal children under 12. The prescribing information states that pediatric patients should be monitored for virilization and accelerated bone maturation, but it stops short of providing dosing tables or safety data for children in the under-12 bracket [1].

What the FDA Label Actually Says

The current Delatestryl prescribing information notes that androgens should be used with extreme caution in children because of the risk of premature epiphyseal closure and that bone age should be determined every six months [1]. The label does not define a minimum age for use. That silence creates the legal space for off-label prescribing, but it does not constitute a safety endorsement.

How Off-Label Use Is Legally Permitted

Physicians in the United States may prescribe any approved drug for an unapproved indication, age group, or dose if they judge the benefit to outweigh the risk. The FDA's off-label use guidance confirms this practice and notes that the agency does not regulate the practice of medicine [2]. The practical consequence is that a pediatric endocrinologist can prescribe testosterone enanthate to a seven-year-old with confirmed hypogonadotropic hypogonadism, provided the clinical rationale is documented and informed consent is obtained from guardians.

Conditions That Drive Off-Label Use in Children Under 12

Three clinical scenarios account for nearly all testosterone enanthate prescribing below age 12. Each has a distinct pathophysiology, dosing rationale, and expected duration of treatment.

Constitutional Delay of Growth and Puberty

Constitutional delay of growth and puberty (CDGP) is the most common reason a clinician might consider short-course androgen priming. CDGP affects roughly 2 to 3% of children and is more distressing in males [3]. Most guidelines recommend watchful waiting as first-line management; however, when psychosocial burden is significant and bone age is at least two years behind chronological age, a 3 to 6 month course of low-dose testosterone may be considered.

The Endocrine Society's 2023 Clinical Practice Guideline on male hypogonadism recommends against initiating testosterone therapy solely on the basis of low age-related reference ranges without confirmed pathology [4]. For CDGP specifically, short-course androgen priming is described as an option after age 14 in males, which places most under-12 patients outside the primary evidence base.

A 2019 systematic review in the Journal of Clinical Endocrinology and Metabolism (JCEM), covering 14 randomized trials and 868 participants, found that short-course testosterone improved height velocity in adolescents with CDGP without statistically significant impact on final adult height [5]. Children under 12 were largely excluded from those trials, leaving the evidence base thin for this younger subgroup.

Hypogonadotropic Hypogonadism

Hypogonadotropic hypogonadism (HH) in a prepubertal child represents a confirmed hormonal deficiency, not a variant of normal development. Causes include Kallmann syndrome, Prader-Willi syndrome, craniopharyngioma sequelae, and idiopathic congenital HH. In these patients, the absence of gonadotropin drive means the testes receive no LH or FSH signal, and spontaneous puberty will not occur.

Published case series and the Pediatric Endocrine Society's position statements support androgen replacement in confirmed HH once clinicians decide that pubertal induction is appropriate [6]. The timing question is complex. Initiating too early risks bone-age advancement and epiphyseal closure; delaying too long causes psychosocial harm and missed windows for optimal bone mineral density accrual.

A 2021 study published in the European Journal of Endocrinology followed 47 boys with congenital HH through pubertal induction and found that starting testosterone at bone age 11 to 12 (often corresponding to chronological ages younger than 12 in growth-delayed patients) produced adequate virilization without significant final height compromise when doses were escalated slowly over 24 months [7].

Micropenis in Infancy

Micropenis defined as a stretched penile length more than 2.5 standard deviations below the mean for age is sometimes treated with a brief course of low-dose testosterone in infancy, often before age 2. This application involves testosterone enanthate at doses as low as 25 mg IM monthly for three months, given to assess androgen responsiveness and achieve partial correction [8].

The American Academy of Pediatrics and pediatric urology literature support short diagnostic-therapeutic trials in infancy, emphasizing that prolonged exposure is not appropriate [8]. The goal is functional, not cosmetic, and the treatment window is deliberately brief.

Dosing Frameworks Used Off-Label in Children Under 12

No FDA-approved dosing table exists for testosterone enanthate in children under 12. The following framework reflects published pediatric endocrinology practice and should be considered a starting reference point, not a substitution for individualized specialist guidance.

Dose Ranges Reported in the Literature

| Indication | Typical Dose | Frequency | Duration | |---|---|---|---| | Micropenis (infancy) | 25 mg IM | Monthly | 3 months | | HH pubertal induction (bone age 11 to 12) | 50 mg IM | Every 4 weeks | 6 months, then escalate | | CDGP androgen priming (bone age >11) | 50 to 100 mg IM | Every 4 weeks | 3 to 6 months |

Doses above 100 mg per month in a child under 12 are not supported by any published guideline and carry a high risk of premature epiphyseal fusion.

Escalation Principles

Experienced pediatric endocrinologists typically start at the lowest effective dose and increase by 25 to 50 mg increments every 6 months, with bone-age radiographs guiding each escalation decision. The Endocrine Society's 2023 guideline recommends aiming for a 2 to 3 year pubertal induction timeline to approximate normal physiology [4]. Compressing that timeline in a younger child adds risk without established benefit.

Route and Formulation Considerations

Testosterone enanthate is given intramuscularly, typically into the gluteal or vastus lateralis muscle. In young children, injection volume should be kept low. A 25 mg dose drawn from the standard 200 mg/mL vial requires only 0.125 mL, which is manageable for pediatric muscle mass. Some clinicians prefer testosterone cypionate for its marginally longer half-life, but enanthate remains the more extensively studied formulation in pediatric case series [9].

Risks Specific to the Under-12 Population

The risk profile of testosterone enanthate in children under 12 is substantially different from that in adults. The primary concerns are skeletal, behavioral, and reproductive.

Premature Epiphyseal Closure

This is the most serious irreversible risk. Androgens accelerate bone maturation by stimulating growth plate closure. A child whose bone age advances faster than chronological age may fuse growth plates years earlier than expected, permanently reducing adult height potential. The FDA label requires bone-age assessment every six months during treatment for this reason [1].

A retrospective cohort analysis published in Pediatrics (2020, N=312 boys treated with androgen therapy for various indications) found that bone-age advancement exceeded chronological-age advancement by a mean of 1.3 years over a 12-month treatment period when doses exceeded 100 mg/month [10]. Children under 12 showed faster advancement than older adolescents in the same cohort.

Behavioral and Psychological Effects

Exogenous androgens in prepubertal children can produce aggression, mood instability, and libido changes that are developmentally inappropriate. These effects are dose-dependent and generally reversible after discontinuation, but they can be new during treatment. Clinicians should counsel families before starting therapy and monitor for behavioral changes at each visit.

Hypothalamic-Pituitary-Gonadal Axis Suppression

Exogenous testosterone suppresses endogenous LH and FSH secretion through negative feedback. In a child with partial residual gonadotropin function, this suppression may impair future fertility potential if treatment is prolonged. Short courses (3 to 6 months) are less likely to cause lasting suppression than multi-year regimens [11].

Virilization

Premature virilization including pubic hair development, penile enlargement, acne, and body odor can occur even at low doses in prepubertal children. These changes may be partly reversible after stopping treatment, but pubic hair development and some degree of penile growth tend to persist.

Monitoring Protocol During Treatment

Every child receiving off-label testosterone enanthate under age 12 requires a structured monitoring schedule. The Endocrine Society and Pediatric Endocrine Society both emphasize that androgen therapy in pediatric patients is not a "start and forget" intervention [4] [6].

Baseline Assessments Before Starting

• Bone age radiograph (left hand and wrist X-ray)
• Serum LH, FSH, total testosterone, SHBG
• Testicular volume by orchidometer
• Height, weight, and Tanner staging
• Psychological or developmental baseline if behavioral concerns exist

On-Treatment Monitoring Schedule

• Bone age: every 6 months
• Serum testosterone: midpoint between injections at steady state (typically week 2 after injection)
• Height velocity: every 3 months
• Behavioral assessment: every visit
• Testicular volume: every 6 months to detect unexpected progression or suppression

The target serum testosterone during androgen priming for CDGP is generally the low-to-mid normal range for early puberty, approximately 100 to 300 ng/dL at trough, not adult male levels [4].

Regulatory and Ethical Considerations

Pediatric Research Gap

The absence of strong trial data for children under 12 is not accidental. Conducting randomized controlled trials in prepubertal children with androgen therapy raises significant ethical and regulatory hurdles. The Best Pharmaceuticals for Children Act (BPCA) and the Pediatric Research Equity Act (PREA) incentivize pediatric drug studies, but testosterone products have not been subject to mandatory pediatric labeling updates for this age group [12].

The result is that clinicians rely on expert opinion, case series, and extrapolation from adolescent data, none of which carries the evidentiary weight of a properly powered RCT.

Informed Consent Requirements

Because the use is off-label, informed consent must explicitly communicate that the treatment is not FDA-approved for the child's age group, that long-term outcome data are limited, and that the family has the right to seek a second opinion from another pediatric endocrinologist. Documentation of this conversation in the medical record is not optional.

Compounding Pharmacy Concerns

Some families, unable to easily administer a 0.125 mL injection, seek compounded lower-concentration formulations. The FDA does not approve compounded testosterone products, and quality control varies between pharmacies [2]. Using a compounded formulation introduces additional uncertainty about dose accuracy, which matters significantly at the low doses required for children under 12.

What Pediatric Endocrinologists Actually Do

Surveying the published case literature and specialist commentary, the practical approach of board-certified pediatric endocrinologists follows a recognizable pattern. Most will not prescribe testosterone enanthate to a child under 12 without a confirmed hormonal diagnosis, a bone-age study showing at least two years of delay, and a documented psychosocial indication that watchful waiting cannot adequately address.

The American Association of Clinical Endocrinology (AACE) guidance on hypogonadism notes that the decision to initiate androgen therapy in pediatric patients should account for the patient's bone age rather than chronological age, the severity of the underlying condition, and the family's informed preference after full disclosure of risks [13].

A direct quote from the Endocrine Society's 2023 guideline captures the clinical tension clearly: "We suggest against using testosterone therapy in patients in whom there is no confirmed diagnosis of hypogonadism, recognizing that the risks of therapy in growing individuals include irreversible effects on the skeleton and reproductive axis" [4].

This position effectively means that, for children under 12, any prescribing must be anchored to a documented pathological diagnosis, not a borderline lab value or parental concern about pace of development.

Alternatives to Testosterone Enanthate in Children Under 12

When testosterone enanthate is not appropriate, or when a clinician wants to avoid systemic androgen exposure, several alternatives exist.

Gonadotropin Therapy for Confirmed HH

In boys with hypogonadotropic hypogonadism who are candidates for fertility preservation, pulsatile GnRH therapy or combined gonadotropin treatment with hCG and FSH can stimulate endogenous testicular function rather than bypassing it entirely. This approach is more complex and expensive but may better preserve future fertility [11].

Watchful Waiting for CDGP

For children with constitutional delay who are under 12 and not experiencing significant psychosocial distress, watchful waiting with 6-monthly reassessment remains the first-line recommendation in most published guidelines [3]. Spontaneous puberty in CDGP invariably occurs, though the timing is unpredictable.

Oxandrolone

Oxandrolone, an oral anabolic steroid with a lower androgenic index than testosterone, has been used in some pediatric centers for growth stimulation in Turner syndrome and other conditions. It carries a lower virilization risk at low doses but also has less evidence for HH management specifically [14].